{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T16:06:34Z","timestamp":1789833994079,"version":"4.0.1"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,19]]},"DOI":"10.7759\/cureus.116542","type":"journal-article","created":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T15:50:07Z","timestamp":1789833007000},"source":"Crossref","is-referenced-by-count":0,"title":["Prolonged Active SARS-CoV-2 Infection in a Patient With Chronic Lymphocytic Leukemia on Venetoclax"],"prefix":"10.7759","author":[{"given":"Brian","family":"Laverentz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nhu","family":"Do","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie A","family":"Jette-Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Schofield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2021.10.031","article-title":"Treatment of chronic or relapsing COVID-19 in immunodeficiency","volume":"149","author":"Brown LK","year":"2022","unstructured":"Brown LK, Moran E, Goodman A, et al.. Treatment of chronic or relapsing COVID-19 in immunodeficiency. J Allergy Clin Immunol. 2022, 149:557-561.e1. 10.1016\/j.jaci.2021.10.031","journal-title":"J Allergy Clin Immunol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1111\/tid.14301","article-title":"Antiviral therapies for the management of persistent coronavirus disease 2019 in immunocompromised hosts: a narrative review","volume":"26","author":"Kinsella PM","year":"2024","unstructured":"Kinsella PM, Moso MA, Morrissey CO, et al.. Antiviral therapies for the management of persistent coronavirus disease 2019 in immunocompromised hosts: a narrative review. Transpl Infect Dis. 2024, 26:e14301. 10.1111\/tid.14301","journal-title":"Transpl Infect Dis"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2024.04.009","article-title":"Persistent COVID-19 in immunocompromised patients-Israeli society of infectious diseases consensus statement on diagnosis and management","volume":"30","author":"Meijer SE","year":"2024","unstructured":"Meijer SE, Paran Y, Belkin A, et al.. Persistent COVID-19 in immunocompromised patients-Israeli society of infectious diseases consensus statement on diagnosis and management. Clin Microbiol Infect. 2024, 30:1012-7. 10.1016\/j.cmi.2024.04.009","journal-title":"Clin Microbiol Infect"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciad181","article-title":"Triple combination therapy with 2 antivirals and monoclonal antibodies for persistent or relapsed severe acute respiratory syndrome coronavirus 2 infection in immunocompromised patients","volume":"77","author":"Mikulska M","year":"2023","unstructured":"Mikulska M, Sepulcri C, Dentone C, et al.. Triple combination therapy with 2 antivirals and monoclonal antibodies for persistent or relapsed severe acute respiratory syndrome coronavirus 2 infection in immunocompromised patients. Clin Infect Dis. 2023, 77:280-6. 10.1093\/cid\/ciad181","journal-title":"Clin Infect Dis"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1097\/QCO.0000000000000841","article-title":"Long and persistent COVID-19 in patients with hematologic malignancies: from bench to bedside","volume":"35","author":"Laracy JC","year":"2022","unstructured":"Laracy JC, Kamboj M, Vardhana SA. Long and persistent COVID-19 in patients with hematologic malignancies: from bench to bedside. Curr Opin Infect Dis. 2022, 35:271-9. 10.1097\/QCO.0000000000000841","journal-title":"Curr Opin Infect Dis"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.945060","article-title":"Case report: long-lasting SARS-CoV-2 infection with post-COVID-19 condition in two patients with chronic lymphocytic leukemia: the emerging therapeutic role of casirivimab\/imdevimab","volume":"12","author":"Ballotta L","year":"2022","unstructured":"Ballotta L, Simonetti O, D'Agaro P, et al.. Case report: long-lasting SARS-CoV-2 infection with post-COVID-19 condition in two patients with chronic lymphocytic leukemia: the emerging therapeutic role of casirivimab\/imdevimab. Front Oncol. 2022, 12:945060. 10.3389\/fonc.2022.945060","journal-title":"Front Oncol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.34988","article-title":"Treatment of chronic COVID-19 with convalescent\/postvaccination plasma in patients with hematologic malignancies","volume":"155","author":"Janssen M","year":"2024","unstructured":"Janssen M, Leo A, Wolf C, et al.. Treatment of chronic COVID-19 with convalescent\/postvaccination plasma in patients with hematologic malignancies. Int J Cancer. 2024, 155:618-26. 10.1002\/ijc.34988","journal-title":"Int J Cancer"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiac.2023.10.022","article-title":"Dual anti-viral treatment for persistent COVID-19 in immunocompromised hemato-oncological patients is associated with a favorable prognosis and minor side effects","volume":"30","author":"Meijer SE","year":"2024","unstructured":"Meijer SE, Halutz O, Adler A, et al.. Dual anti-viral treatment for persistent COVID-19 in immunocompromised hemato-oncological patients is associated with a favorable prognosis and minor side effects. J Infect Chemother. 2024, 30:271-5. 10.1016\/j.jiac.2023.10.022","journal-title":"J Infect Chemother"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.911339","article-title":"Clinical management of patients with B-cell depletion agents to treat or prevent prolonged and severe SARS-CoV-2 infection: defining a treatment pathway","volume":"13","author":"D'Abramo A","year":"2022","unstructured":"D'Abramo A, Vita S, Maffongelli G, et al.. Clinical management of patients with B-cell depletion agents to treat or prevent prolonged and severe SARS-CoV-2 infection: defining a treatment pathway. Front Immunol. 2022, 13:911339. 10.3389\/fimmu.2022.911339","journal-title":"Front Immunol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-023-02125-5","article-title":"Early combination therapy of COVID-19 in high-risk patients","volume":"52","author":"Orth HM","year":"2024","unstructured":"Orth HM, Flasshove C, Berger M, et al.. Early combination therapy of COVID-19 in high-risk patients. Infection. 2024, 52:877-89. 10.1007\/s15010-023-02125-5","journal-title":"Infection"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1186\/s12941-021-00491-2","article-title":"Persistent SARS-CoV-2 infection in patients with secondary antibody deficiency: successful clearance following combination casirivimab and imdevimab (REGN-COV2) monoclonal antibody therapy","volume":"20","author":"Taha Y","year":"2021","unstructured":"Taha Y, Wardle H, Evans AB, et al.. Persistent SARS-CoV-2 infection in patients with secondary antibody deficiency: successful clearance following combination casirivimab and imdevimab (REGN-COV2) monoclonal antibody therapy. Ann Clin Microbiol Antimicrob. 2021, 20:85. 10.1186\/s12941-021-00491-2","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/tid.14055","article-title":"High-titer post-vaccine COVID-19 convalescent plasma for immunocompromised patients during the first omicron surge","volume":"25","author":"Tayyar R","year":"2023","unstructured":"Tayyar R, Wong LK, Dahlen A, Shu E, Pandey S, Liu AY. High-titer post-vaccine COVID-19 convalescent plasma for immunocompromised patients during the first omicron surge. Transpl Infect Dis. 2023, 25:e14055. 10.1111\/tid.14055","journal-title":"Transpl Infect Dis"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/507290-prolonged-active-sars-cov-2-infection-in-a-patient-with-chronic-lymphocytic-leukemia-on-venetoclax","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T15:50:10Z","timestamp":1789833010000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/507290-prolonged-active-sars-cov-2-infection-in-a-patient-with-chronic-lymphocytic-leukemia-on-venetoclax"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,19]]},"references-count":12,"URL":"https:\/\/doi.org\/10.7759\/cureus.116542","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9,19]]}}}